Alf-Åge R. Pettersen

  • MD, PhD
  • +4722117521/+4790535650

Project:ASCET-study(Aspirin non-responsiveness and Clopidogrel clinical Endpoint)

 

Publications 2019

Opstad TB, Kalstad AA, Pettersen AÅ, Arnesen H, Seljeflot I (2019)
Novel biomolecules of ageing, sex differences and potential underlying mechanisms of telomere shortening in coronary artery disease
Exp Gerontol, 119, 53-60
DOI 10.1016/j.exger.2019.01.020, PubMed 30684534

Publications 2018

Langseth MS, Opstad TB, Bratseth V, Solheim S, Arnesen H, Pettersen AÅ, Seljeflot I, Helseth R (2018)
Markers of neutrophil extracellular traps are associated with adverse clinical outcome in stable coronary artery disease
Eur J Prev Cardiol, 25 (7), 762-769
DOI 10.1177/2047487318760618, PubMed 29473463

Publications 2016

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Combined Elevated Levels of the Proinflammatory Cytokines IL-18 and IL-12 Are Associated with Clinical Events in Patients with Coronary Artery Disease: An Observational Study
Metab Syndr Relat Disord, 14 (5), 242-8
DOI 10.1089/met.2015.0130, PubMed 27058587

Opstad TB, Brusletto BS, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease
Immunobiology, 222 (2), 169-175
DOI 10.1016/j.imbio.2016.10.007, PubMed 27765464

Publications 2015

Pettersen AA, Arnesen H, Seljeflot I (2015)
A brief review on high on-aspirin residual platelet reactivity
Vascul Pharmacol, 67-69, 6-9
DOI 10.1016/j.vph.2015.03.018, PubMed 25869498

Publications 2014

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2014)
The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease
PLoS One, 9 (9), e106816
DOI 10.1371/journal.pone.0106816, PubMed 25191702

Publications 2013

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2013)
The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients
PLoS One, 8 (9), e74498
DOI 10.1371/journal.pone.0074498, PubMed 24040261

Publications 2012

Bratseth V, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment
Thromb J, 10 (1), 12
DOI 10.1186/1477-9560-10-12, PubMed 22883224

Njerve IU, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus
Metab Syndr Relat Disord, 10 (6), 400-6
DOI 10.1089/met.2012.0052, PubMed 22897138

Pettersen AÅ, Arnesen H, Opstad TB, Bratseth V, Seljeflot I (2012)
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease
Thromb Res, 130 (3), 424-8
DOI 10.1016/j.thromres.2012.06.016, PubMed 22795340

Pettersen AÅ, Seljeflot I, Abdelnoor M, Arnesen H (2012)
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)
J Am Heart Assoc, 1 (3), e000703
DOI 10.1161/JAHA.112.000703, PubMed 23130135

Publications 2011

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2011)
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study
Cardiovasc Diabetol, 10, 110
DOI 10.1186/1475-2840-10-110, PubMed 22141572

Opstad TB, Pettersen AA, Weiss TW, Akra S, Øvstebø R, Arnesen H, Seljeflot I (2011)
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease
Clin Chim Acta, 413 (1-2), 113-20
DOI 10.1016/j.cca.2011.09.004, PubMed 21963461

Pettersen AA, Arnesen H, Opstad TB, Seljeflot I (2011)
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
Thromb J, 9, 4
DOI 10.1186/1477-9560-9-4, PubMed 21426546

Publications 2010

Opstad TB, Pettersen AA, Bratseth V, Arnesen H, Seljeflot I (2010)
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease
Pathophysiol Haemost Thromb, 37 (2-4), 98-103
DOI 10.1159/000327491, PubMed 21555871

Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I (2010)
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes
Thromb J, 8, 7
DOI 10.1186/1477-9560-8-7, PubMed 20444258

Publications 2006

Solheim S, Pettersen AA, Arnesen H, Seljeflot I (2006)
No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease
Thromb Haemost, 96 (5), 660-4
DOI 10.1160/TH06-06-0337, PubMed 17080224

Publications 2004

Pettersen AA, Müller C, Bendz B, Halvorsen S, Eritsland J, Brekke M, Mangschau A (2004)
[Reduction of myocardial infarction size after primary percutaneous coronary intervention]
Tidsskr Nor Laegeforen, 124 (10), 1387-9
PubMed 15195177

Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H (2004)
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design
Scand Cardiovasc J, 38 (6), 353-6
DOI 10.1080/14017430410024324, PubMed 15804802

Page visits: 3405